CA3125540A1 - Device and method for multidimensional cell culture - Google Patents
Device and method for multidimensional cell culture Download PDFInfo
- Publication number
- CA3125540A1 CA3125540A1 CA3125540A CA3125540A CA3125540A1 CA 3125540 A1 CA3125540 A1 CA 3125540A1 CA 3125540 A CA3125540 A CA 3125540A CA 3125540 A CA3125540 A CA 3125540A CA 3125540 A1 CA3125540 A1 CA 3125540A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- culture
- tissueoids
- cell
- base matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 238000004113 cell culture Methods 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 62
- 229940079593 drug Drugs 0.000 claims abstract description 54
- 230000012010 growth Effects 0.000 claims abstract description 50
- 238000004458 analytical method Methods 0.000 claims abstract description 28
- 230000035945 sensitivity Effects 0.000 claims abstract description 17
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 11
- 238000012512 characterization method Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 264
- 239000011159 matrix material Substances 0.000 claims description 120
- 210000001519 tissue Anatomy 0.000 claims description 56
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 238000001574 biopsy Methods 0.000 claims description 36
- 230000035899 viability Effects 0.000 claims description 25
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 24
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 21
- 239000004744 fabric Substances 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000002054 inoculum Substances 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000010261 cell growth Effects 0.000 claims description 12
- -1 polyethylene terephthalate Polymers 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 6
- 210000002744 extracellular matrix Anatomy 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 102000007469 Actins Human genes 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000000507 anthelmentic effect Effects 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 239000013043 chemical agent Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 239000003365 glass fiber Substances 0.000 claims description 3
- 229920005594 polymer fiber Polymers 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 210000005239 tubule Anatomy 0.000 claims description 3
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 229940125575 vaccine candidate Drugs 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 239000007977 PBT buffer Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000002236 cellular spheroid Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 40
- 229960004679 doxorubicin Drugs 0.000 description 20
- 239000002356 single layer Substances 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 238000004264 monolayer culture Methods 0.000 description 9
- 230000008520 organization Effects 0.000 description 9
- 238000002135 phase contrast microscopy Methods 0.000 description 8
- 229960003989 tocilizumab Drugs 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
- 229960000397 bevacizumab Drugs 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000012835 hanging drop method Methods 0.000 description 6
- 102000058223 human VEGFA Human genes 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 5
- 238000007876 drug discovery Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000003367 anti-collagen effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012604 3D cell culture Methods 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 229940096422 collagen type i Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001707 polybutylene terephthalate Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Chemical class 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000005339 levitation Methods 0.000 description 2
- 201000002250 liver carcinoma Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 238000012605 2D cell culture Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007819 multidimensional cell growth Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000005487 simulated microgravity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 230000025934 tissue morphogenesis Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911000546 | 2019-01-04 | ||
| IN201911000546 | 2019-01-04 | ||
| PCT/IN2020/050011 WO2020141559A2 (en) | 2019-01-04 | 2020-01-04 | Device and method for multidimensional cell culture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3125540A1 true CA3125540A1 (en) | 2020-07-09 |
Family
ID=71407309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3125540A Pending CA3125540A1 (en) | 2019-01-04 | 2020-01-04 | Device and method for multidimensional cell culture |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3906299A4 (ja) |
| JP (1) | JP2022516905A (ja) |
| KR (1) | KR20210124233A (ja) |
| CA (1) | CA3125540A1 (ja) |
| WO (1) | WO2020141559A2 (ja) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266476A (en) * | 1985-06-18 | 1993-11-30 | Yeda Research & Development Co., Ltd. | Fibrous matrix for in vitro cell cultivation |
| US4833083A (en) * | 1987-05-26 | 1989-05-23 | Sepragen Corporation | Packed bed bioreactor |
| DE69633189T2 (de) * | 1995-10-06 | 2005-08-11 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Fester Träger zur Verwendung in der Zellkultivierung, insbesondere für die Kultivierung von Leberzellen, Bioreaktor, welcher den festen Träger enthält, und die Verwendung davon in einem biologisch-künstlichen Lebersystem |
| US5827729A (en) * | 1996-04-23 | 1998-10-27 | Advanced Tissue Sciences | Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue |
| US8367410B2 (en) * | 2003-06-20 | 2013-02-05 | Massachusetts Institute Of Technology | Application of electrical stimulation for functional tissue engineering in vitro and in vivo |
| US7682822B2 (en) * | 2006-03-31 | 2010-03-23 | Aastrom Biosciences, Inc. | Ex vivo generated tissue system |
| EP2183353B1 (en) * | 2007-08-22 | 2015-04-29 | ProBioGen AG | Culture system and method for immunogenicity and immunofunction testing in vitro |
| GB0815427D0 (en) * | 2008-08-22 | 2008-10-01 | Capsant Neurotechnologies S A | Device |
| GB2466481B (en) * | 2008-12-17 | 2013-05-29 | Ucl Business Plc | Improvements in or relating to growing cells |
| CA2919486C (en) * | 2013-08-02 | 2021-11-02 | University Of South Florida | Three dimensional fibrous scaffolds for cell culture |
| US11447743B2 (en) * | 2014-04-22 | 2022-09-20 | Nippon Shokubai Co., Ltd. | Cell culture substrate comprising fluorine-containing polymer on its surface |
| EP3377225A4 (en) * | 2015-11-18 | 2019-07-03 | President and Fellows of Harvard College | CARTRIDGE-BASED SYSTEMS FOR LONG-TERM CULTIVATION OF CELLULAR AGGREGATES |
| CN109496236A (zh) * | 2016-06-06 | 2019-03-19 | 普拉里斯坦有限公司 | 改变的粘附基质细胞及其产生和使用方法 |
-
2020
- 2020-01-04 CA CA3125540A patent/CA3125540A1/en active Pending
- 2020-01-04 KR KR1020217024605A patent/KR20210124233A/ko unknown
- 2020-01-04 JP JP2021538765A patent/JP2022516905A/ja active Pending
- 2020-01-04 WO PCT/IN2020/050011 patent/WO2020141559A2/en unknown
- 2020-01-04 EP EP20736006.6A patent/EP3906299A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210124233A (ko) | 2021-10-14 |
| WO2020141559A2 (en) | 2020-07-09 |
| WO2020141559A3 (en) | 2020-09-17 |
| EP3906299A4 (en) | 2022-10-19 |
| EP3906299A2 (en) | 2021-11-10 |
| JP2022516905A (ja) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zanoni et al. | Anticancer drug discovery using multicellular tumor spheroid models | |
| Pampaloni et al. | The third dimension bridges the gap between cell culture and live tissue | |
| Decarli et al. | Cell spheroids as a versatile research platform: formation mechanisms, high throughput production, characterization and applications | |
| Lee et al. | Engineering liver tissue spheroids with inverted colloidal crystal scaffolds | |
| Rimann et al. | Synthetic 3D multicellular systems for drug development | |
| EP3515600B1 (en) | Organoid arrays | |
| Lin et al. | Recent advances in three‐dimensional multicellular spheroid culture for biomedical research | |
| Ouyang et al. | 3D printing of HEK 293FT cell-laden hydrogel into macroporous constructs with high cell viability and normal biological functions | |
| Pampaloni et al. | Three-dimensional tissue models for drug discovery and toxicology | |
| Ong et al. | Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies | |
| Bratt-Leal et al. | Magnetic manipulation and spatial patterning of multi-cellular stem cell aggregates | |
| JP2017532008A (ja) | 三次元複合細胞凝集体モデル並びにその製造方法及び応用 | |
| Tronser et al. | Miniaturized platform for high-throughput screening of stem cells | |
| Wang et al. | Paper supported long-term 3D liver co-culture model for the assessment of hepatotoxic drugs | |
| KR102578640B1 (ko) | 미세유체 칩을 활용한 오가노이드의 제조 방법 | |
| Rogers et al. | Engineered microfluidic bioreactor for examining the three-dimensional breast tumor microenvironment | |
| Boussommier-Calleja | In vitro models of cancer | |
| Onbas et al. | Fabrication of tunable 3D cellular structures in high volume using magnetic levitation guided assembly | |
| Unger et al. | Human endothelial and osteoblast co-cultures on 3D biomaterials | |
| US20200326330A1 (en) | Device and method for multidimensional cell culture | |
| Okeyo et al. | Minimization of cell-substrate interaction using suspended microstructured meshes initiates cell sheet formation by self-assembly organization | |
| CA3125540A1 (en) | Device and method for multidimensional cell culture | |
| Espinoza-Sánchez et al. | Analyzing the communication between monocytes and primary breast cancer cells in an extracellular matrix extract (ECME)-based three-dimensional system | |
| EP2670857B1 (en) | 3d cell viability assay | |
| US20170130196A1 (en) | Method for culturing and patterning cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |
|
| EEER | Examination request |
Effective date: 20220927 |